MX376830B - Peptido derivado de koc1 y vacuna que lo incluye. - Google Patents

Peptido derivado de koc1 y vacuna que lo incluye.

Info

Publication number
MX376830B
MX376830B MX2017001649A MX2017001649A MX376830B MX 376830 B MX376830 B MX 376830B MX 2017001649 A MX2017001649 A MX 2017001649A MX 2017001649 A MX2017001649 A MX 2017001649A MX 376830 B MX376830 B MX 376830B
Authority
MX
Mexico
Prior art keywords
present
peptide
provides
cytotoxic
cells
Prior art date
Application number
MX2017001649A
Other languages
English (en)
Other versions
MX2017001649A (es
Inventor
Ryuji Osawa
Sachiko Yamashita
Takuya Tsunoda
Tetsuro Hikichi
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2017001649A publication Critical patent/MX2017001649A/es
Publication of MX376830B publication Critical patent/MX376830B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a péptidos de epítopo derivados de KOC1 que tienen la capacidad de inducir células T citotóxicas. La presente invención provee, además, polinucleótidos que codifican el péptido, células presentadoras de antígeno que presentan el péptido y células T citotóxicas que hacen blanco en el péptido, y también métodos de inducción de las células presentadoras de antígeno o CTL. La presente invención también provee composiciones y composiciones farmacéuticas que los contienen como ingrediente activo. Además, la presente invención provee métodos de tratamiento o prevención del cáncer, o prevención de la recurrencia postoperatoria del mismo, usando los péptidos, polinucleótidos, células presentadoras de antígeno, células T citotóxicas o composiciones farmacéuticas de la presente invención. También se proveen métodos de inducción de una respuesta inmune contra el cáncer.
MX2017001649A 2014-08-04 2015-07-31 Peptido derivado de koc1 y vacuna que lo incluye. MX376830B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2014158919 2014-08-04
JP2014158920 2014-08-04
JP2014158921 2014-08-04
PCT/JP2015/071829 WO2016021506A1 (ja) 2014-08-04 2015-07-31 Ｋｏｃ１由来ペプチドおよびそれを含むワクチン

Publications (2)

Publication Number Publication Date
MX2017001649A MX2017001649A (es) 2017-04-27
MX376830B true MX376830B (es) 2025-03-07

Family

ID=55263772

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001649A MX376830B (es) 2014-08-04 2015-07-31 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020004418A MX2020004418A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020011561A MX2020011561A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020004418A MX2020004418A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020011561A MX2020011561A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.

Country Status (16)

Country Link
US (2) US10576102B2 (es)
EP (4) EP3981416B1 (es)
JP (2) JP6754958B2 (es)
KR (2) KR20220155610A (es)
CN (4) CN111925414B (es)
AU (2) AU2015300256B2 (es)
BR (1) BR112017002206A2 (es)
CA (1) CA2956127A1 (es)
DK (1) DK3178838T3 (es)
ES (1) ES2753652T3 (es)
IL (3) IL250175B (es)
MX (3) MX376830B (es)
RU (2) RU2699542C2 (es)
SG (2) SG11201700836TA (es)
TW (3) TW202219059A (es)
WO (1) WO2016021506A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943978B1 (ko) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 신규한 펩타이드
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
WO2020029171A1 (zh) * 2018-08-09 2020-02-13 深圳华大生命科学研究院 无内源hla基因背景的抗原递呈细胞系的构建方法、抗原递呈细胞系及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
JP2004000216A (ja) 2002-04-26 2004-01-08 Kyogo Ito 腫瘍抗原
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP4938451B2 (ja) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
DK2325306T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP2295571A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007013671A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
WO2007097469A1 (en) 2006-02-24 2007-08-30 Oncotherapy Science, Inc. A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer
WO2008007711A1 (en) * 2006-07-11 2008-01-17 Kurume University Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
TW201124530A (en) 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
JP5505944B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
JP5505945B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
JP5505943B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
TWI627182B (zh) 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗

Also Published As

Publication number Publication date
JP2020182487A (ja) 2020-11-12
KR102489834B1 (ko) 2023-01-19
AU2020202435A1 (en) 2020-05-07
TWI754234B (zh) 2022-02-01
US20170333476A1 (en) 2017-11-23
EP3590954A3 (en) 2020-03-25
US20200155596A1 (en) 2020-05-21
CN111925413B (zh) 2025-04-18
EP3981416A3 (en) 2022-07-06
CN111925414A (zh) 2020-11-13
CN106715461B (zh) 2020-11-24
EP3178838B1 (en) 2019-09-18
SG10201900933YA (en) 2019-02-27
WO2016021506A1 (ja) 2016-02-11
CN111925431A (zh) 2020-11-13
JP7070945B2 (ja) 2022-05-18
TW202219059A (zh) 2022-05-16
ES2753652T3 (es) 2020-04-13
EP3981416A2 (en) 2022-04-13
RU2019126629A (ru) 2019-10-08
TWI723958B (zh) 2021-04-11
TW202024122A (zh) 2020-07-01
DK3178838T3 (da) 2019-11-25
CA2956127A1 (en) 2016-02-11
CN111925414B (zh) 2025-04-18
AU2015300256B2 (en) 2020-01-30
SG11201700836TA (en) 2017-03-30
EP4353321A2 (en) 2024-04-17
AU2015300256A1 (en) 2017-02-23
EP3178838A4 (en) 2018-04-25
CN111925431B (zh) 2025-04-15
MX2017001649A (es) 2017-04-27
TW201619189A (zh) 2016-06-01
IL280417B (en) 2022-06-01
IL280417A (en) 2021-03-01
KR20220155610A (ko) 2022-11-23
US11547723B2 (en) 2023-01-10
EP4353321A3 (en) 2024-07-10
BR112017002206A2 (pt) 2017-11-21
MX2020011561A (es) 2020-11-24
IL250175B (en) 2021-02-28
JP6754958B2 (ja) 2020-09-16
EP3590954A2 (en) 2020-01-08
IL287985A (en) 2022-01-01
EP3981416B1 (en) 2024-03-20
US10576102B2 (en) 2020-03-03
EP3178838A1 (en) 2017-06-14
RU2699542C2 (ru) 2019-09-06
JPWO2016021506A1 (ja) 2017-05-18
RU2017106887A (ru) 2018-09-06
AU2015300256A2 (en) 2017-03-16
AU2020202435B2 (en) 2022-05-26
CN106715461A (zh) 2017-05-24
IL250175A0 (en) 2017-03-30
MX2020004418A (es) 2020-08-06
KR20170040319A (ko) 2017-04-12
RU2017106887A3 (es) 2019-02-21
CN111925413A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
PH12017500803A1 (en) Anti-pd-1 antibodies
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019501079A1 (en) Magl inhibitors
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
EA201791095A1 (ru) Способ лечения рака
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IN2014CH00840A (es)
IN2014MU00916A (es)
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
MX2018004308A (es) Peptido derivado de foxm1 y vacuna que lo incluye.
MX2020004418A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
PH12020550791B1 (en) Btk inhibitor compounds
MX2018004305A (es) Peptido derivado de mphosph1 y vacuna que lo incluye.

Legal Events

Date Code Title Description
FG Grant or registration